Data Foundry

Drug recalls 2020

Lamotrigine Tablets — Class I drug recall D-0833-2020

Terminated recall by Taro Pharmaceuticals U.S.A., Inc., reported 2020-02-19, distributed nationwide. Cross Contamination; Lamotrigine Tablets 100 mg USP was contaminated with enalapril maleate.

Recall numberD-0833-2020
Product typeDrug
ClassificationClass I
StatusTerminated
Voluntary or mandatedVoluntary
Recalling firmTaro Pharmaceuticals U.S.A., Inc., Hawthorne, NY, United States
Recall initiated2019-12-20
Classified2020-02-07
Reported by FDA2020-02-19
Terminated2024-02-23
DistributedNationwide (US)
NDC51672-4130, 51672-4130-00, 51672-4130-01, 51672-4130-03, 51672-4130-04, 51672-4130-06, 51672-4131, 51672-4131-00, 51672-4131-01, 51672-4131-03, 51672-4131-04, 51672-4131-06, 51672-4132, 51672-4132-00, 51672-4132-01, 51672-4132-02, 51672-4132-03, 51672-4132-04, 51672-4132-06, 51672-4133, 51672-4133-00, 51672-4133-01, 51672-4133-02, 51672-4133-03, 51672-4133-04 and 1 more
Lot numbers331771
Expiration dates2021-06-20

Product

Lamotrigine Tablets, USP, 100 mg, Rx Only, 100-count bottle, Mfd. by: Taro Pharmaceutical Industries Ltd. Haifa Bay, Israel 2624761 Dist. by: Taro Pharmaceuticals U.S.A., Inc. Hawthorne, NY 10532, NDC 51672-4131-1.

Reason for recall

Cross Contamination; Lamotrigine Tablets 100 mg USP was contaminated with enalapril maleate.

Machine access

This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0833-2020. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.

Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.